Allergan scores year-end FDA nod for CGRP migraine med Ubrelvy, plans early 2020 launch

Allergan’s Ubrelvy, formerly known as ubrogepant, passed FDA gatekeepers Monday, becoming the first oral CGRP drug for the acute treatment of migraines. The med is expected to face 2020 competition from Biohaven’s rimegepant. Allergan plans to launch in the first quarter next year.